The Center for Inquiry encourages FDA to look at the Federal Trade Commission enforcement policy requiring disclaimers for OTC homeopathic drugs' unsubstantiated claims as "the right decision to hold manufacturers accountable."
In a Nov. 16 statement on the FTC policy published Nov. 15, the group that promotes scientific evaluation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?